EMAIL THIS PAGE TO A FRIEND

Oncoimmunology

Antitumor immunization of mothers delays tumor development in cancer-prone offspring.


PMID 26155401

Abstract

Maternal immunization is successfully applied against some life-threatening infectious diseases as it can protect the mother and her offspring through the passive transfer of maternal antibodies. Here, we sought to evaluate whether the concept of maternal immunization could also be applied to cancer immune-prevention. We have previously shown that antibodies induced by DNA vaccination against rat Her2 (neu) protect heterozygous neu-transgenic female (BALB-neuT) mice from autochthonous mammary tumor development. We, herein, seek to evaluate whether a similar maternal immunization can confer antitumor protection to BALB-neuT offspring. Significantly extended tumor-free survival was observed in BALB-neuT offspring born and fed by mothers vaccinated against neu, as compared to controls. Maternally derived anti-neu immunoglobulin G (IgG) was successfully transferred from mothers to newborns and was responsible for the protective effect. Vaccinated mothers and offspring also developed active immunity against neu as revealed by the presence of T-cell-mediated cytotoxicity against the neu immunodominant peptide. This active response was due to the milk transfer of immune complexes that were formed between the neu extracellular domain, shed from vaccine-transfected muscle cells, and the anti-neu IgG induced by the vaccine. These findings show that maternal immunization has the potential to hamper mammary cancer in genetically predestinated offspring and to develop into applications against lethal neonatal cancer diseases for which therapeutic options are currently unavailable.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

860336
3,3′,5,5′-Tetramethylbenzidine, ≥99%
C16H20N2
T2885
3,3′,5,5′-Tetramethylbenzidine, ≥98% (TLC)
C16H20N2
T5525
3,3′,5,5′-Tetramethylbenzidine, tablet, 1 mg substrate per tablet
C16H20N2
87748
3,3′,5,5′-Tetramethylbenzidine, ≥98.0% (NT)
C16H20N2
21888
5(6)-Carboxyfluorescein diacetate N-succinimidyl ester, BioReagent, suitable for fluorescence, ≥90% (HPLC)
C29H19NO11
87444
5-Carboxy-fluorescein diacetate N-succinimidyl ester, for fluorescence, ≥95.0% (HPLC)
C29H19NO11
G7528
D-(+)-Glucose, BioXtra, ≥99.5% (GC)
C6H12O6
G5767
D-(+)-Glucose, ACS reagent
C6H12O6
G7021
D-(+)-Glucose, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.5%
C6H12O6
G5400
D-(+)-Glucose, ≥99% (GC)
C6H12O6
G6152
D-(+)-Glucose, suitable for mouse embryo, ≥99.5% (GC)
C6H12O6
G5146
D-(+)-Glucose, Hybri-Max, powder, BioReagent, suitable for hybridoma
C6H12O6
G7520
D-(+)-Glucose, plant cell culture tested, BioReagent
C6H12O6
49139
D-(+)-Glucose, BioUltra, anhydrous, ≥99.5% (sum of enantiomers, HPLC)
C6H12O6
16325
D-(+)-Glucose, meets analytical specification of Ph. Eur., BP, anhydrous
C6H12O6
608203
D-(+)-Glucose, 99.9 atom % 16O, 99.9 atom % 12C
C6H12O6
D9434
Dextrose, meets EP, BP, JP, USP testing specifications, anhydrous
C6H12O6
D8066
Dextrose, meets EP, BP, JP, USP testing specifications
C6H12O6
SML0196
Resiquimod, ≥98% (HPLC)
C17H22N4O2